Beta-blockers may improve survival in epithelial ovarian cancer
the ONA take:
Beta-blockers, particularly first-generation nonselective beta-blockers, improved overall survival among patients with epithelial ovarian cancer, according to a new study published today in the journal Cancer.
For the study, researchers from The University of Texas MD Anderson Cancer Center in Houston, TX, retrospectively analyzed the medical records of 1,425 women with epithelial ovarian cancer treated between 2000 and 2010 in order to evaluate the impact of beta-blocker use during chemotherapy on overall survival.
Among 269 patients who received beta-blocker therapy, about 72% received beta-1 adrenergic receptor selective agents like atenolol, metoprolol, and bisoprolol, while the rest received nonselective beta-blockers, such as propranolol, carvedilol, and labetalol.
Results showed that median overall survival for beta-blocker and non-beta-blocker users was 47.8 months and 42 months, respectively.
Researchers found that patients receiving selective beta-1 blockers had a median overall survival of 94.9 months vs 38 months for those receiving non-selective beta antagonists.
The researchers note, however, that further studies are required before beta-blockers are recommended as adjuvant therapy in patients with ovarian cancer undergoing surgery.
Beta-blockers, particularly first-generation nonselective beta-blockers, improved overall survival among patients with epithelial ovarian cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
- Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care
- Pediatric Patients, Parents Overreport Adherence to ALL Medication Regimen
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|